Anderson Kristin G, Ribas Antoni
Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, Virginia, USA
University of California Los Angeles, Los Angeles, California, USA.
J Immunother Cancer. 2025 Aug 25;13(8):e013061. doi: 10.1136/jitc-2025-013061.
DNA mismatch repair deficiency has been identified as a biomarker that strongly correlates with tumor response to anti-programmed cell death protein-1 (PD-1) checkpoint blockade therapy in the metastatic setting. In a promising Phase 2 study published in the , Cercek demonstrate that PD-1 checkpoint blockade also has potential in the neoadjuvant setting and may eliminate the need for surgical intervention. These results offer great hope to patients with a variety of solid malignancies because those who experience complete clinical responses may be able to safely choose non-operative management to preserve organ function and minimize side effects associated with surgery.
DNA错配修复缺陷已被确定为一种生物标志物，在转移性环境中，它与肿瘤对抗程序性细胞死亡蛋白1（PD-1）检查点阻断疗法的反应密切相关。在发表于《 》的一项很有前景的2期研究中，塞尔捷克证明PD-1检查点阻断在新辅助治疗中也具有潜力，并且可能无需手术干预。这些结果给患有各种实体恶性肿瘤的患者带来了巨大希望，因为那些经历完全临床缓解的患者或许能够安全地选择非手术治疗，以保留器官功能并将与手术相关的副作用降至最低。
